Keros Therapeutics, Inc. (KROS)
11.73
+0.18
(+1.56%)
USD |
NASDAQ |
Apr 15, 16:00
11.73
0.00 (0.00%)
After-Hours: 18:53
Keros Therapeutics Research and Development Expense (Annual) : 127.09M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics, Inc. | 1.493B |
| Amicus Therapeutics, Inc. | 135.84M |
| MannKind Corp. | 66.35M |
| PTC Therapeutics, Inc. | 455.25M |
| Insmed, Inc. | 771.09M |